NCT03482024

A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function

Pharmacokinetics of Tirzepatide Following Administration to Subjects With Impaired Renal Function

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 45 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.

Conditions

• Renal Insufficiency
• End Stage Renal Disease

Interventions

Type	Name	Description
DRUG	Tirzepatide	Administered SC.

Timeline

• Start date: 2018-03-30
• Primary completion: 2019-08-19
• Completion: 2019-08-19
• First posted: 2018-03-29
• Last updated: 2023-03-23
• Results posted: 2023-03-23

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study